A Study of ASKG712 in Patients With Diabetic Macular Edema - Trial NCT05940428
Access comprehensive clinical trial information for NCT05940428 through Pure Global AI's free database. This Phase 1 trial is sponsored by AskGene Pharma, Inc. and is currently Not yet recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AskGene Pharma, Inc.
Timeline & Enrollment
Phase 1
Jul 30, 2023
Jul 01, 2025
Primary Outcome
1. Incidence of ocular adverse events (AEs) of the study eyes,2. Incidence of non-ocular AEs
Summary
This multicenter, non-randomized, open-label, multiple-dose-escalation and dose-expansion
 study will investigate the safety, tolerability, pharmacokinetics and efficacy of ASKG712
 following intravitreal administration in patients with diabetic macular edema (DME).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05940428
Non-Device Trial